HomeCompareVPAHF vs ARCC

VPAHF vs ARCC: Dividend Comparison 2026

VPAHF yields 270.27% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VPAHF wins by $759.41M in total portfolio value
10 years
VPAHF
VPAHF
● Live price
270.27%
Share price
$0.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$759.43M
Annual income
$439,524,286.02
Full VPAHF calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — VPAHF vs ARCC

📍 VPAHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVPAHFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VPAHF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VPAHF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VPAHF
Annual income on $10K today (after 15% tax)
$22,972.97/yr
After 10yr DRIP, annual income (after tax)
$373,595,643.12/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, VPAHF beats the other by $373,595,642.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VPAHF + ARCC for your $10,000?

VPAHF: 50%ARCC: 50%
100% ARCC50/50100% VPAHF
Portfolio after 10yr
$379.73M
Annual income
$219,762,143.58/yr
Blended yield
57.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

VPAHF
No analyst data
Altman Z
2.9
Piotroski
3/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VPAHF buys
0
ARCC buys
13
PoliticianChamberTickerTypeAmountDate
John Fetterman🏛 Senate$ARCC▲ Buy$1,001 - $15,0002025-09-09
John Fetterman🏛 Senate$ARCC▼ Sell$1,001 - $15,0002025-09-04
Ashley Moody🏛 Senate$ARCC▲ Buy$15,001 - $50,0002025-04-04
John Fetterman🏛 Senate$ARCC▲ Buy$1,001 - $15,0002025-02-18
Dave McCormick🏛 Senate$ARCC▲ Buy$250,001 - $500,0002025-01-17
Pete Sessions🏢 House$ARCC▼ Sell$1,001 - $15,0002023-11-01
Pete Sessions🏢 House$ARCC▲ Buy$569.252023-10-06
Pete Sessions🏢 House$ARCC▲ Buy$0 - $1,0002023-10-06
Pete Sessions🏢 House$ARCC▲ Buy$155.922023-08-15
Pete Sessions🏢 House$ARCC▲ Buy$0 - $1,0002023-08-15
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVPAHFARCC
Forward yield270.27%10.65%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$759.43M$24.5K
Annual income after 10y$439,524,286.02$1.14
Total dividends collected$726.21M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: VPAHF vs ARCC ($10,000, DRIP)

YearVPAHF PortfolioVPAHF Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$37,727$27,027.03$11,373$532.74+$26.4KVPAHF
2$135,662$95,294.33$12,608$279.46+$123.1KVPAHF
3$465,409$320,250.45$13,809$142.90+$451.6KVPAHF
4$1,524,778$1,026,790.34$15,042$72.20+$1.51MVPAHF
5$4,775,420$3,143,907.74$16,341$36.27+$4.76MVPAHF
6$14,311,885$9,202,185.51$17,732$18.18+$14.29MVPAHF
7$41,088,348$25,774,630.79$19,231$9.10+$41.07MVPAHF
8$113,120,635$69,156,102.86$20,851$4.55+$113.10MVPAHF
9$298,977,565$177,938,485.31$22,605$2.28+$298.95MVPAHF
10$759,430,280$439,524,286.02$24,504$1.14+$759.41MVPAHF

VPAHF vs ARCC: Complete Analysis 2026

VPAHFStock

Volpara Health Technologies Limited provides breast imaging analytics software products in New Zealand. The company offers Volpara Analytics, a software that optimize breast cancer screening operations; Volpara Live, which provides instant patient-based image quality feedback; Volpara Lung, a patient management software that streamlines lung screening workflow; and Volpara Patient Hub, a customizable mammography reporting and patient communications software. It also offers Volpara Risk, an integration with Patient Hub that uses TC8 to calculate patients' risk of developing breast cancer; Volpara Risk Pathways, a program for identifying and managing high-risk breast cancer screening patients; Volpara Scorecard, which displays patient breast density and risk insights essential for improved clinical decision-making and early detection; and Volpara Science, an AI-based software that powers Volpara software products. In addition, the company provides TruDensity, a Volpara clinical function; TruPGMI, a Volpara clinical function, which uses artificial intelligence to automatically and objectively assess the positioning of the patient and resulting image quality; TruPressure, a Volpara clinical function, which determines whether the compression pressure applied by the radiographer is in the sweet spot that yields quality images, minimal radiation exposure, and the least discomfort; and TruRadDose, a Volpara clinical function which analyses the radiation dose delivered to patients based on their breast density. It operates in North America, the Asia Pacific, Europe, the Middle East, and Africa. Volpara Health Technologies Limited has a strategic relationship with RevealDx. The company was incorporated in 2009 and is headquartered in Wellington, New Zealand.

Full VPAHF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this VPAHF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VPAHF vs SCHDVPAHF vs JEPIVPAHF vs OVPAHF vs KOVPAHF vs MAINVPAHF vs HTGCVPAHF vs GBDCVPAHF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.